Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Few treatment options exist for patients with myelofibrosis (MF), and their survival is significantly shortened. Activating mutation of the JAK2 tyrosine kinase (JAK2(V617F)) is found in approximately 50% of MF patients. CEP-701 is a tyrosine kinase inhibitor that inhibits JAK2 in in vitro and in vi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Santos, Fabio P. S., Kantarjian, Hagop M., Jain, Nitin, Manshouri, Taghi, Thomas, Deborah A., Garcia-Manero, Guillermo, Kennedy, Debra, Estrov, Zeev, Cortes, Jorge, Verstovsek, Srdan
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2010
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081385/
https://ncbi.nlm.nih.gov/pubmed/20008298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-10-246363
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars